Abstract
RETINOIDS regulate many biological processes, including differen-tiation, morphogenesis and cell proliferation1–3. They are also important therapeutic agents, but their clinical usefulness is limited because of side effects4–8. Retinoid activities are mediated by speci-fic nuclear receptors, the RARs and RXRs, which can induce tran-scriptional activation through specific DNA sites3,9–11 or by inhibiting the transcription factor AP-1 (refs 12–15), which usually mediates cell proliferation signals16. Because the two types of receptor actions are mechanistically distinct12, 15, we investigated whether conformationally restricted retinoids, selective for each type of receptor action, could be identified. Here we describe a new class of retinoids that selectively inhibits AP-1 activity but does not activate transcription. These retinoids do not induce differentiation in F9 cells but inhibit effectively the proliferation of several tumour cell lines, and could thus serve as candidates for new retinoid therapeutic agents with reduced side effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lotan, R. Biochim. Biophys. Acta 605, 33–91 (1981).
Roberts, A. B. & Sporn, M. B. in The Retinoids (eds Sporn, M. B., Roberts, A. B. & Goodman, D. S.) 209–286 (Academic, Orlando, 1984).
Morris-Kay, G. (ed.). Retinoids in Normal Development and Teratogenesis (Oxford Science, Oxford, 1992).
Bollag, W. & Holdener, E. E. Ann. Oncol. 3, 513–526 (1994).
Kraemer, K. H. et al. New Engl. J. Med. 318, 1633–1637 (1988).
Smith, M. A. et al. J. clin. Oncol. 10, 839–864 (1992).
Huang, M. et al. Blood 72, 567–572 (1988).
Hong, W. K. et al. New Engl. J. Med. 323, 795–801 (1990).
Leid, M, Kastner, P. & Chambon, P. Trends biochem. Sci. 17, 427–433 (1992).
Zhang, X-k. & Pfahl, M. Trends Endocrin. Metab. 4, 10–16 (1993).
Pfahl, M. Semin. Cell Biol. 5, 95–103 (1994).
Yang-Yen, H. F. et al. New Biol. 3, 1206–1219 (1991).
Schüle, R. et al. Proc. natn. Acad. Sci. U.S.A. 88, 6092–6096 (1991).
Salbert, G. et al. Molec. Endocrin. 7, 1347–1356 (1993).
Pfahl, M. Endocr. Rev. 14, 651–658 (1993).
Angel, P. & Karin, M. Biochim. biophys. Acta 1072, 129–157 (1991).
Lehmann, J. M. et al. Cancer Res. 51, 4804–4809 (1991).
Graupner, G. et al. Biochem. biophys. Res. Commun. 179, 1554–1561 (1991).
Delescluse, C. et al. Molec. Pharmac. 40, 556–562 (1991).
Lehmann, J. M. et al. Science 258, 1944–1946 (1992).
Dawson, M. I. & Okamura, W. H. (eds) Chemistry and Biology of Synthetic Retinoids (CRC, Boca Raton, 1990).
Lee, M-O., Dawson, M. I. & Pfahl, M. Proc. natn. Acad. Sci. U.S.A. 91, 5632–5636 (1994).
Apfel, C. et al. Proc. natn. Acad. Sci. U.S.A. 89, 7129–7133 (1992).
Titcomb, M. S. et al. Molec. Endocrin. 8, 870–877 (1994).
Hu, L. & Gudas, L. J. Molec. cell. Biol. 10, 391–396 (1990).
Vasios, G. et al. EMBO J. 10, 1149–1158 (1991).
Liang, P. & Pardee, A. B. Science 257, 967–971 (1992).
Hussmann, M. et al. Molec. cell. Biol. 11, 4097–4103 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fanjul, A., Dawson, M., Hobbs, P. et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372, 107–111 (1994). https://doi.org/10.1038/372107a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/372107a0
This article is cited by
-
All trans retinoic acid alleviates coronary stenosis by regulating smooth muscle cell function in a mouse model of Kawasaki disease
Scientific Reports (2021)
-
Selective antagonism of cJun for cancer therapy
Journal of Experimental & Clinical Cancer Research (2020)
-
UTX/KDM6A suppresses AP-1 and a gliogenesis program during neural differentiation of human pluripotent stem cells
Epigenetics & Chromatin (2020)
-
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
Nature Cancer (2020)
-
SR 11302, an AP-1 Inhibitor, Reduces Metastatic Lesion Formation in Ex Vivo 4D Lung Cancer Model
Cancer Microenvironment (2017)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.